India, July 29 -- Wednesday, Splash Beverage Group, Inc. (SBEV) announced the expansion of its exclusive global license for CannEpil to include veterinary therapeutic applications, gaining access to significant companion-animal oncology and pain-management markets.
CannEpil is a proprietary pharmaceutical-grade cannabinoid formulation consisting of cannabidiol and tetrahydrocannabinol isolates formulated in an oral liquid solution.
With this move, the company has exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions.
Also, Splash will pay Argent BioPharma Limited a 10 percent royalty on net revenues generated from veterinary applications of CannEpil.
goog...